Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

A fixed‐dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium‐glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Four studies were conducted under fasted conditions to demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fediuk, Daryl J., Matschke, Kyle, Liang, Yali, Pelletier, Kathleen B., Wei, Hua, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851892/
https://www.ncbi.nlm.nih.gov/pubmed/31219248
http://dx.doi.org/10.1002/cpdd.722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851892/
https://www.ncbi.nlm.nih.gov/pubmed/31219248
http://dx.doi.org/10.1002/cpdd.722

Ejemplares similares